Use access key #2 to skip to page content.

Closing Incyte (INCY) underperform

Recs

1

March 11, 2008 – Comments (2) | RELATED TICKERS: INCY

Incyte has hit a price level that I like a lot better for the current pipeline. Now I'm going to get aggressive, turn around and give it a thumbs up. There's definitely an ongoing potential for short term pain, but we're at a very early stage of the life cycle and at some point Incyte is going back into the teens. There's also a potential for a monster gap up a la Pharmasset or Rigel with impressive phase II data.

2 Comments – Post Your Own

#1) On March 11, 2008 at 11:58 AM, PDTBiotech (93.25) wrote:

Hey zz - I dig your id name.  I see Incyte is developing some JAK2 inhibitors.  Do you know of anyone trying to develop Stat3 or Stat5 inhibitors for breast cancer - or, for anything, I guess?  I used to work in a breast cancer lab, and one thing that always jumped out in that field was that breast cancer tends to have a much lower percentage of mutations in p53 than other cancers, it tends to be downregulated rather than actually mutated.  Stat3 has been shown to be a direct transcriptional repressor of p53, and Stat activation seems to be a major culprit in breast cancer.  Stats are notoriously difficult to develop inhibitors to because they don't have a kinase domain and the SH3 domains don't provide much for chemists to target, so JAK inhibitors are the next best thing.  I've only seen some small labs in academia developing Stat3 inhibitors, and they're not very good, but would be very interested in any company that had a Stat3 inhibitor with good pharmicokinetics and strong activity.

Report this comment
#2) On April 10, 2008 at 1:08 PM, zzlangerhans (99.74) wrote:

I'm the wrong guy to ask as I'm out of basic science now for 10 years. I'm just trying to valuate biotech pipelines based on where their products stand in clinical trials and probable future demand, taking most of the science on faith. I try to spot the ones that are obviously snake oil (Neurochem, Hemispheryx, Prana etc.) and stay away from them. And nothing's been working. As you may have seen for yourself, stock prices and scientific validity rarely travel together in the small cap biotech world.   

Report this comment

Featured Broker Partners


Advertisement